ABOUT
WHY WE EXIST
We draw our inspiration from the courage and determination of the patients we serve
We were not founded to be just one the among crowd of pharmaceutical companies but to radically transform the evolving landscape of cancer technology therapies. The unified purpose of our diverse team allows us to innovate by working together, challenging and supporting one another to go further, look deeper, take risks, shift perspectives, and make the scientific advances that transform our drug therapies into our ultimate goal of wiping cancer off of the face of the earth.
We are a patient focused clinical stage biopharmaceutical company with the goal of curing pancreatic cancer by being etiology-centric. It is through the understanding of the cause of the disease that drives our scientific research and innovations of novel therapies.
OUR VISION
We dare to imagine a world where the cure is possible. The courage and determination of the people we serve has motivated us to push beyond the barriers that once confined our scientific understanding. Diagnoses that were once looked upon as incurable are shifting, with new thinking, new research, and new design in therapies. At the very core of Vitalgenics pioneering advancements is our etiology-centric approach. We draw on our deep experience and understanding of the underlying causes of one of the most challenging diseases, pancreatic cancer. As we have discovered the molecular structure of pancreatic cancer cells and how the sequences form, grow, and metastasis tumors only then did we develop a novel cancer therapy that stays on target. It is the tremendous investment of time and resources in understanding the cause of the cancer and the cascade that allow us to innovate the transformative solutions on the frontiers of oncology. Being governed by our high standard of values and motivated by our heart for the patients and their families that will benefit from our novel therapies, we are relentless in our pursuit of the cure that will transform lives.
OUR TEAM
Our team is comprised of world-class leaders, renowned oncology specialists and acclaimed microbiologists that have spent a lifetime researching and developing scientific technologies and refining business strategies and that are united by one mission.

JOEY EDGE

CHIEF EXECUTIVE OFFICER

Joey Edge, CEO founded the Edge Companies in 1991 where he has experienced a very productive 29-year history. He expanded Edge financial holdings into Life Science technologies in 2016 when he launched Genesis Global. His range of leadership roles at Genesis Global was developing new health and personal care product innovations based in novel peptide technology, brand development and procuring national and international distribution channels.

In 2018 opportunities at Genesis Global led to the launching of a new biomedical company named Vitalgenics to bring stem cell therapies to the forefront of regenerative medicine. In 2020 he successfully merged Vitalgenics with Willow Croft Health and his longtime friend, Charles Owen to bring over 170 years of renown biotechnology to the forefront of the discovery of novel cancer therapies. During his entrepreneurial career, he has held a variety of executive positions of increasing responsibility in product development, operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of health care products.
Joey has had a very successful career as an innovative leader. He is focused on achieving positive results through strong leadership, effective communication, interpersonal relations, and excellent analytical skills. His successes have been the result of disrupting the status quo and revolutionizing normal thinking and processes. His innovative and pragmatic approach has led to developing strategic partnerships and synergies with functional leaders to effectively bridge the gap between the needs of clients, business objectives, operational decisions, and financial targets while continuing to contain costs and drive profitable growth. Joey is known as a motivated catalyst and he relies on an ethical foundation, business acumen, and the ability to execute effectively.

CHARLES OWEN

CHIEF FINANCIAL OFFICER

Charles Owen CFO, studied Molecular biology at the University of Denver and began his professional career serving as a microbiology researcher for 17 years. His career path successfully led to his many accomplishments as an applied scientist where he has spent his professional career focused on the multidrug resistance of Pancreatic cancer, bacterial infection, cell mediated immunity, mast cells and mast cell stabilizers and how they apply to cell immune mediated diseases. His targeted research and study of diseases and the cause led to his scientific expertise in the discovery and understanding the cell mediated immune stress response cascade, Ca2+, the inflammatory response and how these relate to the multidrug resistance in Pancreatic cancer, bacterial infection, cell-mediated immune diseases and targeted organ therapy. His corporate leadership began in 2009 when he founded Willowcroft Pharma where his roles led to his experience working with the FDA, Contract Research Organizations, collaborating with academic Institutions, and other BioPharma companies. He developed expertise in clinical study protocols, toxicity studies, target therapy, and drug delivery applications. In early 2020 he brought his knowledge and expertise to join his longtime friend and associate Joey Edge at Vitalgenics to create a totally new concept in the pharmaceutical industry.

Charles was the first to use mast cell stabilizers as an injectable drug delivery system along with using the compounds in the regional limb perfusion technique in animals. Mr. Owen currently holds 2 patents.

DOUGLAS M. COLDWELL
PhD, MD, FSIR, FSIO, FACR

CHIEF MEDICAL OFFICER

Dr. Douglas M. Coldwell is an internationally recognized expert in local regional therapy of cancer. He has pioneered numerous treatments for cancer, including the use of radioactive particles delivered through the arteries to treat tumors typically in the liver but which can be found anywhere. He was the first to use a probe that treats metastatic tumors in the spine by heating them with a bipolar radiofrequency ablation probe and then reinforcing the bone with cement to halt pain. The combination of radiofrequency ablation of the tumor and the reinforcing cement stabilizes the spine and allows improved quality of life.

After Dr. Coldwell received his BA and PhD in Materials Science from Rice University in Houston, TX, he had a stint teaching solid state physics and researching for Texas Instruments, Inc. He attended medical school at the University of Texas Medical Branch at Galveston, performed his internship and residency at the Pennsylvania State University Medical School at Hershey, PA, and followed with his fellowship in Cancer Interventional Radiology at University of Texas System Cancer Center, M.D. Anderson Cancer Center. He is Board Certified in both Diagnostic and Interventional Radiology. Dr. Coldwell is a Fellow of the Society of Interventional Radiology, the American College of Radiology, and the American Heart Association. He has been on numerous university faculties, frequently lectures internationally, and has authored over 100 peer reviewed papers.

VIVEK SHARMA, MD, FACP

CHIEF MEDICAL ADVISOR & ONCOLOGY SPECIALIST

Dr. Vivek Sharma is an Associate Professor in the division of Medical Oncology/Hematology at the University of Louisville in Kentucky with a clinical focus in the treatment of GI cancers and coagulation disorders. He completed medical school in India and then did his Internal Medicine residency and Hematology/Oncology fellowship at the University of Louisville. He is board certified in Medical Oncology, Hematology and Internal Medicine and is involved in clinical and translational research in his areas of focus to advance the science to advance understanding and treatment of these disorders.

CRAIG D. LOGSDON, Ph.D.

CHIEF SCIENCE ADVISOR

Graduated Suma Cum Laude from California State University with a Bachelor of Science in Biology, and he earned a Ph. D. in Physiology from the University of California. He also received a Post Doctoral Fellowship at the Department of Physiology with the Cystic Fibrosis Foundation, at the University of California. His long and distinguished professional career began in 1983 as a Research Associate in the cell biology laboratory at Mt. Zion Hospital in San Francisco while also serving as an Adjunct Lecturer in the Department of Physiology at the University of California. In 1987 he was promoted to the position of Senior Research Investigator at Mount Zion Hospital and Medical Center and became the Assistant Professor in Residence in the Department of Physiology at the University of California. He was recruited in 1987 to become the Assistant Professor in the Department of Physiology at University of Michigan. He was promoted to Associate Professor in 1992 and six years later in 1998 promoted to Professor where he served until 2004. He was recruited by the University of Texas – MD Anderson Cancer Center to hold the distinguished position as Lockton Distinguished Chair for Pancreatic Cancer. He served as Professor in the Department of Gastrointestinal in Medical Oncology and as Professor in the Department of Cancer Biology. He has served as the past President of the American Pancreatic Association, the Scientific Advisory Board of the National Pancreas Foundation, and served on the Scientific Advisory Board of the Pancreatic Cancer Action Network (PanCan). Association. He has published 137 Peer-Reviewed original research articles, 19 Invited articles and was the cocreator of 2 patents.